Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13175642 | 0.89 | MAPT (0.52) | ALDH1A1MAPTMAPK1NPC1RAB9A | |
| SCHEMBL13956739 | 0.85 | MAPT (0.69) | ALDH1A1MAPTNPC1RAB9AKDM4E | |
| SCHEMBL2862926 | 0.85 | MAPT (0.68) | ALDH1A1MAPTNPC1RAB9AKDM4E | |
| SCHEMBL13956741 | 0.83 | MAPT (0.72) | ALDH1A1MAPTNPC1RAB9AKDM4E | |
| SCHEMBL13175915 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MAPTMAPK1NPC1RAB9A | |
| SCHEMBL13175990 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MAPTMAPK1NPC1RAB9A | |
| SCHEMBL4364694 | 0.82 | MAPT (0.49) | ALDH1A1MAPTMAPK1NPC1RAB9A | |
| SCHEMBL2919415 | 0.81 | ALDH1A1 (0.51) | ALDH1A1MAPTMAPK1NPC1RAB9A | |
| SCHEMBL2919440 | 0.81 | ALDH1A1 (0.51) | ALDH1A1MAPTMAPK1NPC1RAB9A | |
| SCHEMBL2943801 | 0.80 | MAPT (0.47) | ALDH1A1MAPTKDM4EHPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709047-B1 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-09-01 | — | — | EP | claimed |
| US-7439374-B2 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | claimed |
| US-20050228013-A1 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2005-10-13 | — | — | US | claimed |
| EP-1709047-B1 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-1709047-B1 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-09-01 | — | — | EP | disclosed |
| US-7439374-B2 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439374-B2 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439374-B2 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20050228013-A1 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228013-A1 | Azabenzofuran substituted thioureas; inhibitors of viral replication | NAT1, PIGS, ADORA1 | ALDH1A1 171/4885MAPT 4359/4885MAPK1 3423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.